特利加压素诱发糖尿病患者外周缺血性坏疽

Terlipressin-induced Peripheral Ischemic Gangrene in a Diabetic Patient.

作者信息

Sarma Phulen, Muktesh Gaurav, Dhaka Narender, Ruhela Rakesh, Mishra Abhishek, Singh Rahul, Sinha Saroj K, Medhi Bikash, Kochhar Rakesh

机构信息

Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

J Pharmacol Pharmacother. 2017 Jul-Sep;8(3):148-150. doi: 10.4103/jpp.JPP_42_17.

DOI:10.4103/jpp.JPP_42_17

PMID:29081628

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5642133/

Abstract

Terlipressin is used commonly in the management of hepatorenal syndrome and acute variceal bleeding. Like its parent compound vasopressin, it is also notorious for its ischemic complications. Terlipressin-induced ischemic complications can virtually affect any part of the body, but the incidence of serious complications is less than its parent compound vasopressin. Here, we report a case of terlipressin-induced peripheral ischemic gangrene in a diabetic male, which ultimately led to death of the patient.

摘要

特利加压素常用于肝肾综合征和急性静脉曲张出血的治疗。与它的母体化合物血管加压素一样，它也因缺血性并发症而声名狼藉。特利加压素引起的缺血性并发症几乎可累及身体的任何部位，但严重并发症的发生率低于其母体化合物血管加压素。在此，我们报告一例糖尿病男性患者因特利加压素导致外周缺血性坏疽，最终患者死亡的病例。